Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolytic agents in development

M Verstraete1, H R Lijnen, D Collen

  • 1Center for Molecular and Vascular Biology, University of Leuven, Belgium.

Drugs
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impaired fibrinolysis and the risk for coronary heart disease.

Circulation·1996
Same author

Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.

European journal of biochemistry·1996
Same author

Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure.

Thrombosis and haemostasis·1996
Same author

Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.

Circulation·1996
Same author

A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis.

Thrombosis and haemostasis·1996
Same author

Role of tissue factor in embryonic blood vessel development.

Nature·1996
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Researchers are developing novel thrombolytic agents, including engineered plasminogen activators (PAs) and natural compounds like fibrolase and staphylokinase, to improve clot-busting therapies for thrombosis.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Current thrombolytic agents require improvement in potency, specificity, and fibrin selectivity.
  • Research is exploring various strategies to develop superior thrombolytic therapies.

Purpose of the Study:

  • To review advancements in thrombolytic agent development.
  • To highlight novel agents derived from genetic engineering, animal sources, and bacterial origins.

Main Methods:

  • Construction of mutant and chimaeric plasminogen activators (PAs).
  • Characterization and cloning of PAs from vampire bat saliva.
  • Production of recombinant fibrolase from southern copperhead snake venom.
  • Development of recombinant staphylokinase.

Related Experiment Videos

Main Results:

  • Engineered PAs show enhanced properties like prolonged half-life and inhibitor resistance.
  • Vampire bat PA shares homology with human t-PA but has structural differences.
  • Fibrolase directly degrades fibrin and fibrinogen without activating plasminogen.
  • Recombinant staphylokinase is a potent, fibrin-specific activator of plasminogen.

Conclusions:

  • Novel thrombolytic agents, including engineered PAs, fibrolase, and staphylokinase, demonstrate significant therapeutic potential.
  • These agents offer improved potency, specificity, and fibrin selectivity over existing treatments.
  • Further research and clinical studies are warranted to fully evaluate their efficacy and safety in treating thrombosis.